I'll take either one of those estimates in the near term honestly. The important thing, as I see it, isn't the initial spike. It's the fact that once we have an approval, the sky is the limit for this drug and this company.

Shortly thereafter, we uplist and begin generating massive revenue. Big institutions get involved, a broader investment base gets involved, etc. So while the initial spike could be big - my guess would be $10, I think we are easily at +$25 at some point this Summer. The other possibility is someone trying to buy the whole company for $30-$50 per share (or higher). That may be cheap as a long-term price, but I wouldn't turn my nose up at 10X in less than a year personally.

Bring on that first approval - it's going to change the game for us!!